The SSRI That Kept a Little Dopamine
IUPAC: (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine · freebase MW 306.23 g/mol · C₁₇H₁₇Cl₂N · CAS 79617-96-2 (HCl 79559-97-0)
Sertraline (Zoloft, Lustral). A selective serotonin reuptake inhibitor built on a rigid cis-aminotetralin scaffold rather than the flexible phenylpropylamine of fluoxetine. Sub-nanomolar at SERT — yet quietly the most dopamine-transporter-avid SSRI on the market, the pharmacological fingerprint that sets it apart from the rest of the class. First-line for depression and the anxiety spectrum; among the preferred antidepressants in pregnancy and lactation.
Sertraline is a competitive, non-transported inhibitor of the serotonin transporter (SERT, SLC6A4). Like cocaine, it binds the orthosteric S1 central site and physically blocks the pore without being carried across the membrane — but where cocaine is a promiscuous DAT>NET>SERT blocker, sertraline is the mirror image: SERT-dominant, with sub-nanomolar affinity (Ki ≈ 0.075 nM). Occupancy of SERT stalls the transporter in an outward-open state, 5-HT accumulates in the synapse, and — over weeks — postsynaptic adaptation (5-HT1A autoreceptor desensitization, raphé disinhibition) produces the antidepressant effect.
The 2018 crystal structure of the human transporter with sertraline bound (PDB 6AWO, ligand code SRE) shows the dichlorophenyl ring buried in subsite B of the S1 pocket, the tetralin core wedged against subsite A, and the protonated methylamine hydrogen-bonded to Asp98 — the same aspartate that coordinates the amine of serotonin itself. Competitive inhibition, resolved at 3.5 Å.
Sertraline locks SERT (Ki ≈ 0.075 nM, DrugMatrix) in the outward-open conformation. The 3,4-dichlorophenyl group occupies subsite B; the ammonium salt-bridges Asp98. Serotonin reuptake fails and synaptic 5-HT rises.
Sertraline blocks the dopamine transporter at Ki ≈ 25.8 nM — the highest DAT affinity of any marketed SSRI, ~50–100× tighter than fluoxetine, paroxetine, or citalopram at DAT. Weak dopamine-reuptake inhibition is baked into the molecule (see §04).
Norepinephrine-transporter block is weak (Ki ≈ 977 nM), ~13,000× less potent than at SERT. Sertraline is not a functional noradrenergic drug at therapeutic plasma levels; its selectivity ratio keeps it firmly "S" in SSRI.
Sertraline binds the sigma-1 chaperone (Ki ≈ 29 nM) — actually as an antagonist, unlike fluvoxamine's agonism. σ1 modulation of ER-stress and Ca²⁺ signaling is a proposed contributor to onset kinetics and to the class's antioxidant/neuroplastic effects.
SERT carries a second, low-affinity vestibular (S2) site. SSRIs including sertraline can occupy it, slowing dissociation from S1. This allosteric self-potentiation stabilizes the drug-bound outward-open state and sharpens functional selectivity.
The fused bicyclic aminotetralin is conformationally locked — closer to cocaine's tropane than to fluoxetine's freely-rotating chain. It arrives pre-organized, paying a small conformational-entropy penalty on binding (see §05 FlexAID∆S).
Sertraline is orally absorbed slowly (Tmax 4.5–8.4 h) and — unusually for an SSRI — its bioavailability increases with food. Plasma protein binding is high (~98%), the volume of distribution is very large (~20 L/kg), and the terminal half-life of ~26 h supports once-daily dosing with steady state reached in about a week. Clearance is almost entirely hepatic and multi-enzyme, which makes sertraline relatively forgiving of any single CYP polymorphism.
Metabolism cascade: the dominant route is N-demethylation to N-desmethylsertraline, catalyzed chiefly by CYP2B6 with contributions from CYP2C19, CYP2C9, CYP2D6 and CYP3A4. The desmethyl metabolite is far weaker at SERT (~10–20× less potent) and is clinically inactive as an antidepressant despite its long half-life. Both parent and metabolite then undergo oxidative deamination to a ketone, reduction, hydroxylation, and glucuronide conjugation before excretion.
Sertraline is a moderate, dose-dependent CYP2D6 inhibitor — clinically milder than paroxetine or fluoxetine but not negligible above 150 mg/day (relevant when co-prescribed with 2D6 substrates such as tamoxifen, metoprolol, or tricyclics). It is a weak inhibitor of CYP3A4/2C19. This comparatively clean interaction profile is one reason sertraline is a workhorse first-line agent rather than a specialist's drug.
Raising synaptic 5-HT is instantaneous; feeling better is not. The therapeutic lag (2–6 weeks) reflects downstream neuroadaptation — autoreceptor desensitization, BDNF/TrkB signaling, hippocampal neuroplasticity — not the transporter block itself, which is maximal within hours. Sertraline carries broad FDA indications: major depression, OCD, panic disorder, PTSD, social anxiety disorder, and PMDD.
SERT blockade across the raphé–limbic–cortical axis elevates 5-HT at 5-HT1A, 5-HT2A/2C and 5-HT3 receptors. Amygdala reactivity falls; prefrontal top-down control strengthens; cortico-striato-thalamic loops relevant to OCD are dampened. This is the shared SSRI mechanism — sertraline is simply among the most potent and selective expressions of it.
Sertraline's meaningful DAT affinity gives it a whisper of dopamine-reuptake inhibition that its SSRI siblings lack. Clinically this is invoked to explain its slightly more activating, occasionally energizing profile and anecdotally lower anhedonia — though at therapeutic doses striatal DAT occupancy is modest (well under the threshold of a stimulant) and the clinical magnitude remains debated. It is pharmacology worth naming, not overselling.
Sertraline is one of the preferred SSRIs in pregnancy and breastfeeding: it has extensive reproductive safety data, low breast-milk transfer (among the lowest relative infant doses of the class), and — unlike paroxetine, which carries a first-trimester cardiac-malformation signal — no consistent major teratogenicity. Residual considerations are late-pregnancy neonatal adaptation syndrome (jitteriness, feeding difficulty, transient) and a small absolute increase in persistent pulmonary hypertension of the newborn (PPHN). Untreated maternal depression carries its own substantial risks; the decision is a balance, not a prohibition.
Sertraline has the highest rate of diarrhea among the common SSRIs. The gut houses ~90% of the body's serotonin; blocking enteric SERT floods 5-HT3 and 5-HT4 receptors on enteric neurons, accelerating motility and secretion. Nausea and loose stools are typically dose-related, front-loaded in the first two weeks, and often self-limiting. Taking the dose with food and titrating slowly blunts it. Sexual dysfunction (delayed orgasm, low libido) is the other high-prevalence, often persistent, class effect.
Every SSRI is defined by SERT potency. What separates sertraline is its second-place target. In the classic Tatsumi (1997) and Owens (1997) transporter panels — and in the internally consistent DrugMatrix radioligand set used here — sertraline's dopamine-transporter affinity (Ki ≈ 25.8 nM) is roughly one to two orders of magnitude tighter than that of fluoxetine, paroxetine, citalopram, or fluvoxamine, whose DAT Ki values sit in the high-hundreds-of-nM to low-µM range.
SERT : DAT : NET ≈ 0.075 : 25.8 : 977 nM. The SERT/DAT ratio (~340×) still leaves SERT overwhelmingly dominant — sertraline is a true SSRI, not a functional DRI. But the absolute DAT number is what matters for class-comparison: 25.8 nM is stimulant-adjacent binding affinity, even if the receptor occupancy achieved at antidepressant plasma levels is modest.
Structural echo of cocaine: both molecules pair a rigid polycyclic core with a chlorinated/benzoyl aromatic and a basic amine, and both trap monoamine transporters in the outward-open state. Sertraline's stereochemistry and scaffold simply steer that shared pharmacophore toward SERT — with just enough DAT left over to be interesting.
So what? The clinical read is cautious: the dopaminergic component may contribute to sertraline's activating feel and is a plausible partial explanation for its slightly distinct tolerability, but it does not make sertraline reinforcing or abusable at therapeutic doses. It is a mechanistic curiosity with a modest, real, and frequently overstated clinical shadow.
Sertraline's aminotetralin core is conformationally locked — the fused bicyclic ring system has only two
rotatable bonds (ChEMBL: RTB = 2), far fewer than fluoxetine's flexible phenoxypropylamine chain. In FlexAID∆S modeling
this means a small conformational-entropy penalty (ΔS_conf) on binding: the ligand is nearly
pre-organized in solution, so little translational/rotational freedom is surrendered when it seats into the S1 pocket.
A rigid, high-affinity binder — the same thermodynamic logic that makes cocaine's tropane so DAT-avid.
SERT itself is a conformationally restless alternating-access transporter, cycling outward-open → occluded →
inward-open. Its unbound S1 vestibule samples many rotamer states — a high pocket Shannon entropy H_pocket.
Sertraline binding, anchored by the Asp98 salt bridge and the dichlorophenyl fit into subsite B, collapses that
conformational ensemble into a single outward-open microstate. This sharp entropy collapse is the
thermodynamic signature of a sub-nanomolar competitive inhibitor freezing a flexible protein.
The theoretical binding free energy from the observed SERT Ki ≈ 0.075 nM is
ΔG = −RT·ln(1/Ki) ≈ −13.9 kcal/mol at 298 K — extraordinarily favorable, and consistent with a
low entropic cost (rigid ligand) added to a large enthalpic gain (salt bridge + halogenated hydrophobic packing).
The much smaller entropy-collapse signal at DAT — a looser, higher-Ki fit — is exactly what a
FlexAID∆S ∆S fingerprint would predict for a selectivity gap of ~340× between the two transporters.
Sertraline is one of the safest antidepressants in overdose and among the most-prescribed drugs on earth. The dangerous edges are specific and predictable: serotonergic combinations, abrupt stopping, and high-dose cardiac effects.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
SERT
Serotonin transporter (SLC6A4)
|
Ki = 0.075 nM
Primary target
|
Reuptake inhibitor | |
|
DAT
Dopamine transporter (SLC6A3)
|
Ki = 25.8 nM
SSRI outlier
|
Reuptake inhibitor | |
|
σ1R
Sigma-1 receptor (SIGMAR1)
|
Ki = 29.3 nM
57 nM (lit.)
|
Antagonist | |
|
NET
Norepinephrine transporter (SLC6A2)
|
Ki = 977 nM
Minimal
|
Weak inhibitor |